GRAL Stock Analysis: GRAIL | NASDAQ
Diagnostics & Research | NASDAQ, USA | Market Cap: 3.355m USD | 12M Return: 142.7% | US3847471014 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 55.3M
Qual. Beats: 0
Rev. Trend: 98.5%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 2.1 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
GRAIL, Inc. (NASDAQ: GRAL) is a commercial-stage healthcare company that markets multi-cancer early detection (MCED) tests and related services in the United States and select international markets. Its lead product, Galleri, is a blood-based screening test intended for asymptomatic adults aged 50 and older, and the company also provides a diagnostic aid designed to help clinicians accelerate diagnostic resolution for patients with clinical suspicion of cancer.
Beyond screening, GRAIL offers development services such as support for clinical studies, pilot testing, research collaborations, and therapy development partnerships with biopharmaceutical companies. The company is also building a precision oncology franchise built around a research-use-only (RUO) targeted methylation-based platform, with applications spanning disease prognostication, risk stratification, minimal residual disease (MRD) detection, and recurrence/relapse monitoring.
GRAIL sits within the biotechnology sub-industry of healthcare, a segment in which methylation-based liquid biopsy has become a leading technology for non-invasive cancer detection and disease monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California, and completed its public listing on NASDAQ in June 2024.
- Galleri test revenue growth accelerates US and international adoption
- FDA approval pathway for Galleri multi-cancer screening test advances
- NHS-Galleri trial results support reimbursement coverage decisions
| Net Income: -391.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.10 > 0.02 and ΔFCF/TA 3.37 > 1.0 |
| NWC/Revenue: 502.9% < 20% (prev 432.8%; Δ 70.13% < -1%) |
| CFO/TA -0.10 > 3% & CFO -294.7m > Net Income -391.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 10.95 > 1.5 & < 3 |
| Outstanding Shares: last quarter (43.1m) vs 12m ago 22.99% < -2% |
| Gross Margin: -10.83% > 18% (prev -56.53%; Δ 45.70% > 0.5%) |
| Asset Turnover: 5.96% > 50% (prev 4.97%; Δ 0.99% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.29 (Total Current Assets 914.7m - Total Current Liabilities 83.5m) / Total Assets 2.84b |
| B: -3.66 (Retained Earnings -10.4b / Total Assets 2.84b) |
| C: -0.20 (EBIT TTM -559.2m / Avg Total Assets 2.77b) |
| D: 8.45 (Book Value of Equity 2.54b / Total Liabilities 301.0m) |
| Altman-Z'' = -2.51 = D |
| DSRI: 0.98 (Receivables 19.8m/16.4m, Revenue 165.3m/134.3m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.88 (AQ_t 0.63 / AQ_t-1 0.71) |
| SGI: 1.23 (Revenue 165.3m / 134.3m) |
| TATA: -0.03 (NI -391.6m - CFO -294.7m) / TA 2.84b) |
| Beneish M = -2.95 (Cap -4..+1) = A |
As of September 22, 2026, the stock is trading at USD 107.97 with a total of 3,519,996 shares traded. Over the past week, the price has changed by +42.95%, over one month by +35.74%, over three months by +73.86% and over the past year by +142.74%.
Current recommended Stop Loss: 102.90 (which is 4.7% or 1.1 ATR below the current price).
GRAIL has received a consensus analysts rating of 3.50. Therefore, it is recommended to hold GRAL.
- StrongBuy: 1
- Buy: 0
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 77 | -28.7% |
P/S = 20.3003
P/B = 1.3331
Revenue TTM = 165.3m USD
EBIT TTM = -559.2m USD
EBITDA TTM = -403.9m USD
Long Term Debt = 80.6m USD (estimated: total debt 91.3m - short term 10.7m)
Short Term Debt = 10.7m USD (from shortTermDebt, last quarter)
Debt = 91.3m USD (from shortLongTermDebtTotal, last quarter) (leases 91.3m already included)
Net Debt = -770.3m USD (calculated: Debt 91.3m - CCE 861.6m)
Enterprise Value = 2.58b USD (3.35b + Debt 91.3m - CCE 861.6m)
Interest Coverage Ratio = unknown (Ebit TTM -559.2m / Interest Expense TTM 0.0)
EV/FCF = -8.75x (Enterprise Value 2.58b / FCF TTM -295.3m)
FCF Yield = -11.42% (FCF TTM -295.3m / Enterprise Value 2.58b)
FCF Margin = -178.7% (FCF TTM -295.3m / Revenue TTM 165.3m)
Net Margin = -236.9% (Net Income TTM -391.6m / Revenue TTM 165.3m)
Gross Margin = -10.83% ((Revenue TTM 165.3m - Cost of Revenue TTM 183.2m) / Revenue TTM)
Gross Margin QoQ = -28.12% (prev 47.91%)
Tobins Q-Ratio = 0.91 (Enterprise Value 2.58b / Total Assets 2.84b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 91.3m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -441.8m (EBIT -559.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 10.95 (Total Current Assets 914.7m / Total Current Liabilities 83.5m)
Debt / Equity = 0.04 (Debt 91.3m / totalStockholderEquity, last quarter 2.54b)
Debt / EBITDA = 1.91 (negative EBITDA) (Net Debt -770.3m / EBITDA -403.9m)
Debt / FCF = 2.61 (negative FCF - burning cash) (Net Debt -770.3m / FCF TTM -295.3m)
Total Stockholder Equity = 2.47b (last 4 quarters mean from totalStockholderEquity)
RoA = -14.12% (Net Income -391.6m / Total Assets 2.84b)
RoE = -15.88% (Net Income TTM -391.6m / Total Stockholder Equity 2.47b)
RoCE = -21.97% (EBIT -559.2m / Capital Employed (Equity 2.47b + L.T.Debt 80.6m))
RoIC = -15.99% (negative operating profit) (NOPAT -441.8m / Invested Capital 2.76b)
WACC = 14.64% (E(3.35b)/V(3.45b) * Re(15.04%) + D(91.3m)/V(3.45b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 15.04% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 95.93 | Cagr: 15.70%
[DCF] Fair Price = unknown (Cash Flow -295.3m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.34 | # QB: 0
Revenue Correlation: 98.46 | Revenue CAGR: 25.73% | SUE: 0.98 | # QB: 1
EPS current Quarter (2026-09-30): EPS=-2.24 | Chg30d=+8.61% | Revisions=+25% | Analysts=4
EPS current Year (2026-12-31): EPS=-7.10 | Chg30d=+7.45% | Revisions=+25% | GrowthEPS=+39.2% | GrowthRev=+23.0%
EPS next Year (2027-12-31): EPS=-8.94 | Chg30d=+9.45% | Revisions=+25% | GrowthEPS=-25.8% | GrowthRev=+25.3%
[Analyst] Revisions Ratio: +50% (up=3, down=0)